{
    "clinical_study": {
        "@rank": "156261", 
        "arm_group": {
            "arm_group_label": "Long Term Follow up", 
            "arm_group_type": "Other", 
            "description": "Long Term follow up of patients who received StarGen\u2122  in a previous study"
        }, 
        "brief_summary": {
            "textblock": "The purpose of the study is to examine the long term safety of an experimental gene transfer\n      agent, StarGen\u2122, designed to treat Stargardt Macular Degeneration."
        }, 
        "brief_title": "A Study to Determine the Long Term Safety, Tolerability and Biological Activity of StarGen\u2122 in Patients With Stargardt's Macular Degeneration", 
        "completion_date": {
            "#text": "October 2030", 
            "@type": "Anticipated"
        }, 
        "condition": "Stargardt Disease", 
        "condition_browse": {
            "mesh_term": "Macular Degeneration"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Must have received a subretinal injection of StarGen\u2122\n\n          -  Must have completed protocol SG1/001/10 to Week 48 or undergone an early\n             discontinuation visit.\n\n        Exclusion Criteria:\n\n          -  Did not receive StarGen\u2122as part of the SG1/001/10 protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01736592", 
            "org_study_id": "SG1/002/11"
        }, 
        "intervention": {
            "arm_group_label": "Long Term Follow up", 
            "intervention_name": "StarGen", 
            "intervention_type": "Drug", 
            "other_name": "Long Term follow up of patients who received StarGen\u2122 in a previous study"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 29, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97239"
                    }, 
                    "name": "Oregon Health & Science University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75012"
                    }, 
                    "name": "Centre National d'Ophtalmologie des Quinze-Vingts"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "France"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Label Study to Determine the Long Term Safety, Tolerability and Biological Activity of StarGen\u2122 in Patients With Stargardt's Macular Degeneration", 
        "overall_official": [
            {
                "affiliation": "Oregon Health and Science University", 
                "last_name": "David Wilson, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Centre National d'Ophtalmologie des Quinze-Vingts", 
                "last_name": "Jos\u00e9-Alain Sahel, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "October 2030", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The number of patients with treatment emergent adverse events", 
            "measure": "The incidence of Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "15 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01736592"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The change from baseline function relative to the contralateral eye utilising retinal analytical techniques", 
            "measure": "Delay in retinal degeneration", 
            "safety_issue": "No", 
            "time_frame": "15 years"
        }, 
        "source": "Oxford BioMedica", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Oxford BioMedica", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}